This new tool, called Gallium PSMA (Prostate-Specific Membrane Antigen), was produced on-site using a computer-controlled automated system. The Caen Normandy University Hospital thus becomes the first center in western Normandy to produce this innovative drug, joining several leading medical centers worldwide.
Gallium PSMA specifically targets prostate tumor cells, opening new perspectives for early detection, personalized treatment and therapeutic monitoring for patients with this cancer, the most common in men.
Thanks to this cutting-edge technology, physicians will be able to detect tumor boundaries with unparalleled precision, thus optimizing treatment strategies and reducing complications and side effects. Furthermore, Gallium PSMA plays a crucial role in therapeutic monitoring by assessing the cancer's response to treatment. This allows physicians to adjust treatment protocols reactively, providing personalized care and improving clinical outcomes.
The first patient benefited from this technique on Friday, June 16, 2023, at the Caen Normandy University Hospital. This milestone marks a turning point in the field of nuclear medicine in Normandy and positions the radiopharmacy unit at the Caen Normandy University Hospital as a pioneer in the field.
Professor Denis Agostini, head of the nuclear medicine & theranostics, also underlines the continued commitment of the Caen Normandy University Hospital to providing quality and state-of-the-art care to patients with prostate cancer and expresses his pride and gratitude to the radiopharmacy team and especially to the work of Dr Jonathan Vigne and Dr Maïté Esnault for this major advance.
The Caen Normandy University Hospital, the region's leading expert referral center, remains committed to pursuing its efforts in research and development of new diagnostic and therapeutic solutions to combat prostate cancer and other serious diseases.
